Trending Topic

2 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

From advances in targeted therapies to the integration of AI and steps towards precision medicine, 2024 brought many exciting developments in the field. With 2025 now unfolding, many of these are likely to continue gaining momentum and potentially redefine patient care. In this latest edition of touchREVIEWS in RMD, we’re excited to present a collection […]

Search Results

Showing Results for Arthritis

Speciality Filter

Select Specialty or Clinical Area

Clear All
Update Filters
Close Popup
Coverage from: EULAR Highlights

The Phase II ARGO trial evaluated the IL-17A and IL-17F inhibitor sonelokimab in psoriatic arthritis, showing promising clinical efficacy and significant improvements in patient-reported outcomes (PROs). In this interview, Prof. Laure Gossec highlights how sonelokimab reduced disease burden and improved quality of life, emphasizing the importance of PROs in assessing treatment effectiveness and guiding future development.

Mark CompleteCompleted
BookmarkBookmarked

Interstitial lung disease (ILD) is a common and potentially fatal complication of systemic autoimmune rheumatic diseases (SARDs), such as rheumatoid arthritis (RA) and systemic sclerosis (SSc). ILD may be the first sign of disease or develop later, often with variable clinical courses. Early detection is critical, as delayed diagnosis contributes to poor outcomes. In response, the 2023 American College of Rheumatology (ACR) guidelines emphasize routine screening and risk-based strategies to improve identification and management of SARD-associated ILD (SARD-ILD).

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.

Mark CompleteCompleted
BookmarkBookmarked

What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career doctors ready to think beyond the bedside and explore the business of medicine.

Mark CompleteCompleted
BookmarkBookmarked

In this interview with Dr. Stuart Silverman, we discuss his WCO-IOF-ESCEO 2025 presentation on the clinical utility of bone turnover markers (BTMs) in osteoporosis care. BTMs such as s-CTX and s-PINP, standardized by the IOF-IFCC, provide insights into bone remodelling, support treatment monitoring, guide therapy adjustments, and help personalize drug holidays, though they complement rather than replace traditional diagnostic tools.

Mark CompleteCompleted
BookmarkBookmarked

touchREVIEWS in RMD is proud to welcome Dr Vinod Ravindran to our editorial board. With a distinguished background in clinical rheumatology, medical education, and research, Dr Ravindran is widely recognized for his contributions to advancing care and understanding in the field.

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.

Mark CompleteCompleted
BookmarkBookmarked

Nominated Future Leader, Dr Tom Appleton, shares insights into his career, osteoarthritis research, and the role of immunology in shaping future OA treatments. In this interview, Dr Appleton discusses the importance of early intervention, the impact of synovial macrophage dysfunction, and emerging therapies that could revolutionize rheumatology. His work bridges clinical care and research to drive innovation in osteoarthritis management and autoimmune disease.

Mark CompleteCompleted
BookmarkBookmarked

Osteoarthritis is increasingly recognised as a heterogeneous disease with diverse clinical phenotypes and molecular endotypes. In this expert Q&A, Professor Ali Mobasheri discusses how precision medicine—through clinical phenotyping and molecular endotyping—can guide targeted therapies, accelerate the development of disease-modifying treatments, and transform OA management into a personalised, proactive approach that improves patient outcomes.

Mark CompleteCompleted
BookmarkBookmarked

At the 2025 WCO-IOF-ESCEO congress, Professor Philip Conaghan presented the safety and efficacy findings from the phase 2 study of LEVI-04 for the treatment of adults with knee osteoarthritis. LEVI-04 is a first-in-class, NT-3 inhibitor, which works by targeting the inflammatory pathways involved in joint degeneration and selectively inhibiting pro-inflammatory cytokines.

Mark CompleteCompleted
BookmarkBookmarked

The European Commission has approved upadacitinib for treating giant cell arteritis (GCA) in adults. This marks the first oral JAK inhibitor approved for GCA in the EU. Backed by the findings from the phase III SELECT-GCA trial, upadacitinib offers a new option for managing this chronic inflammatory disease in adults.

Mark CompleteCompleted
BookmarkBookmarked

In this edition of our Future Leaders series, we speak with Dr. Santhanam Sham, a rising star in rheumatology. As a Senior Consultant at Kauvery Hospitals, Chennai, Dr. Sham is dedicated to advancing research on autoimmune diseases like SLE and vasculitis, while also fostering patient-centric care and embracing cutting-edge medical technologies.

Mark CompleteCompleted
BookmarkBookmarked

From advances in targeted therapies to the integration of AI and steps towards precision medicine, 2024 brought many exciting developments in the field. With 2025 now unfolding, many of these are likely to continue gaining momentum and potentially redefine patient care. In ...

Mark CompleteCompleted
BookmarkBookmarked

Rheumatoid arthritis (RA) is one of the most challenging autoimmune diseases. Early, targeted and effective therapy is crucial for achieving remission and preventing long-term joint destruction. Over the past two decades, tumour necrosis factor (TNF) inhibitors (TNFi) have been the ...

Mark CompleteCompleted
BookmarkBookmarked

To gain expert insight into the most impactful developments of the past year and the trends set to shape the next, we reached out to our esteemed expert faculty. From advances in targeted therapies to the integration of AI and steps towards precision medicine, here’s what our experts had to say.

Mark CompleteCompleted
BookmarkBookmarked

The use of immune checkpoint inhibitors (ICIs) in treating cancer has greatly improved survival outcomes, particularly in patients with advanced disease for whom successful treatment options have previously been limited. For example, in patients with metastatic melanoma, the median survival ...

Mark CompleteCompleted
BookmarkBookmarked

Join us as we unveil the content that made the greatest impact in 2024. From insightful Q&As and news articles to engaging podcasts, conference highlights, and medical education resources, this year has been filled with valuable content designed to support your daily practice and, ultimately, enhance patient care.

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

Recent advancements made in understanding the pathology of inflammatory skin conditions have enabled JAK inhibitors, initially developed for haematology over 20 years ago, to be investigated for dermatological use. In this episode, Dr William (Bill) Damsky discusses JAK inhibitors’ journey from proof-of-concept to treating a wide range of skin conditions, their future impact on rare diseases and the debate around safety.

Load More...
Close Popup